Evidence map›Paper›PMID 26504383›Full record

ArticleInternational journal of nanomedicine2015

Combination of glycosphingosomes and liposomal doxorubicin shows increased activity against dimethyl-α-benzanthracene-induced fibrosarcoma in mice.

Masood A Khan, Ahmed N Aljarbou, Yousef H Aldebasi, Mohammed S Alorainy, Arif Khan

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Masood A KhanCollege of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
Ahmed N AljarbouCollege of Pharmacy, Qassim University, Buraydah, Saudi Arabia.
Yousef H AldebasiCollege of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
Mohammed S AlorainyCollege of Medicine, Qassim University, Buraydah, Saudi Arabia.
Arif KhanCollege of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
Buraydah Colleges · SAQassim University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to assess the antitumor effect of glycosphingolipid-incorporated liposomes (glycosphingosomes) in combination with liposomal doxorubicin (Lip-Dox) in a mouse model of fibrosarcoma. Glycosphingosomes were prepared by incorporating glycosphingolipids isolated from Sphingomonas paucimobilis into the liposomes of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, cholesterol, and cardiolipin. Tumors were induced by administering dimethyl-α-benzanthracene, and tumor-bearing mice were treated with various formulations of Dox, including free Dox, Lip-Dox, or glycosphingosomes + Lip-Dox. Mice were observed for 90 days to monitor their survival and tumor size. Free Dox, but not Lip-Dox or a combination of glycosphingosomes and Lip-Dox, caused the substantial depletion of leukocytes and significantly increased the levels of lactate dehydrogenase and creatinine kinase in mice. Tumor-bearing mice treated with a combination of glycosphingosomes and Lip-Dox showed restricted tumor growth and increased survival when compared to those treated with free Dox or Lip-Dox. The results of the present study suggest that a combination of glycosphingosomes and Lip-Dox may prove to be very effective in the treatment of tumors.

Indexed as

1,2-Dipalmitoylphosphatidylcholine9,10-Dimethyl-1,2-benzanthraceneAnimalsCell ProliferationChemistry, PharmaceuticalDoxorubicinFemaleFibrosarcomaMicePolyethylene GlycolsSurvival Analysis1,2-Dipalmitoylphosphatidylcholine9,10-Dimethyl-1,2-benzanthracenecolfosceril palmitateDoxorubicinliposomal doxorubicinPolyethylene GlycolschemotherapyglycosphingolipidsNKT cellstumors

Identifiers

PMID26504383
PMCPMC4605236
OpenAlexW1875075516

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.